Pay in 4 interest-free payments of $5.36 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Background and aims: CT-388 is a cAMP signal-biased dual GLP-1 and GIP receptor agonist for weekly sc administration for chronic weight management and glycemic control
Headache: Pain relievers such as acetaminophen or ibuprofen may alleviate symptoms
For example, just 0.04% of people on semaglutide or tirzepatide developed NAION, compared with 0.02% of people on other diabetes medications
The competitive landscape is intensifying with over 60 late-stage pipeline assets in China and looming semaglutide biosimilars, escalating pressure on pricing, differentiation and market access
These forward-looking statements are not historical facts but rather are based on the Companys current expectations, estimates, and projections about its industry, its beliefs, and assumptions
